Carcinogenesis Advance Access originally published online on December 4, 2008
Carcinogenesis 2009 30(2):230-237; doi:10.1093/carcin/bgn272
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PPAR
is a ligand-dependent negative regulator of vitamin D3-induced monocyte differentiation


1 Department of Biomedical Sciences, University of Modena and Reggio Emilia, 41100 Modena, Italy
2 Ergentech laboratory of genetics and biotechnology
3 Department of Biology, University of Padova, Padova 35121, Italy
* To whom correspondence should be addressed. Dipartimento di Scienze Biomediche, Sezione di Chimica Biologica, Università di Modena e Reggio Emilia, Via Campi 287, 41100 Modena, Italy. Tel: +39 059 2055409; Fax: +39 059 2055410; Email: alexis.grande{at}unimore.it
A number of reports indicate that peroxisome proliferator-activated receptor (PPAR)
is involved in the molecular control of monocyte–macrophage differentiation. In this regard, the recent demonstration that PPAR
is a primary response gene of 1
,25-dihydroxyvitamin D3 (VD), i.e. a powerful inducer of such process, allowed us to hypothesize the existence of a cross talk between PPAR
and VD receptor pathways. To address this issue, we analyzed the effects promoted by stimulation with PPAR
ligands and by overexpression of this nuclear receptor in monoblastic cell lines undergoing exposure to VD. The results obtained evidenced that, although promoting a weak differentiation effect by themselves, PPAR
ligands efficiently co-operated with VD treatment. In spite of this, PPAR
overexpression exerted a remarkable inhibitory effect on monocyte–macrophage differentiation induced by VD that was, at least partly, reverted by stimulation with a highly specific PPAR
ligand. These data indicate that, although acting through a ligand-dependent modality, PPAR
is a negative regulator of VD-mediated monocyte differentiation, allowing us to hypothesize a role of the investigated nuclear receptor in the differentiation block of M5 type (monoblastic) acute myeloid leukemias (AMLs). Bioinformatic analysis of a microarray database, containing the expression profiles of 285 AML cases, further supported this hypothesis demonstrating the existence of a subset of M5 type (monoblastic) AMLs that overexpress PPAR
gene.
Abbreviations: AA, arachidonic acid; AML, acute myeloid leukemia; cDNA, complementary DNA; cPGI, carbaprostacyclin; FAB, French-American-British classification; mRNA, messenger RNA; NGFR, nerve growth factor receptor; PCR, polymerase chain reaction; PMA, phorbol l2-myristate l3-acetate; PPAR, peroxisome proliferator-activated receptor; QRT, quantitative reverse transcription; RT, reverse transcription; siRNA, small interference RNA; VD, 1
,25-dihydroxyvitamin D3; VDR, vitamin D receptor
These authors contributed equally to this work. Received July 1, 2008; revised November 1, 2008; accepted November 29, 2008.